Recent advancements in molecular diagnostics, such as testing for DUSP22 and TP63 rearrangements, could offer valuable insights into ALK-negative ALCL prognosis and aid in distinguishing it from peripheral T-cell lymphoma (PTCL) NOS (5, 15). Here, TP63 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.